ACHROMYCIN V Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Achromycin V, and when can generic versions of Achromycin V launch?
Achromycin V is a drug marketed by Avet and Lederle and is included in two NDAs.
The generic ingredient in ACHROMYCIN V is tetracycline hydrochloride. There are ninety-nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the tetracycline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Achromycin V
A generic version of ACHROMYCIN V was approved as tetracycline hydrochloride by WATSON LABS on December 31st, 1969.
Summary for ACHROMYCIN V
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 66 |
| Patent Applications: | 4,308 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ACHROMYCIN V at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ACHROMYCIN V
US Patents and Regulatory Information for ACHROMYCIN V
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avet | ACHROMYCIN V | tetracycline hydrochloride | CAPSULE;ORAL | 050278-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Avet | ACHROMYCIN V | tetracycline hydrochloride | CAPSULE;ORAL | 050278-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Lederle | ACHROMYCIN V | tetracycline hydrochloride | SUSPENSION;ORAL | 050263-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
